Mitochondrial disorders as a mechanism for the development of obese Sarcopenia

Obese sarcopenia is a severe and prevalent disease in an aging society. Compared to sarcopenia alone, the development and advanced stage of obesity sarcopenia is faster and more severe. Diagnosis of the cause of adipocyte accumulation is also more complicated; however, no effective pharmacological t...

Full description

Saved in:
Bibliographic Details
Published in:Diabetology and metabolic syndrome 2023-11, Vol.15 (1), p.1-224, Article 224
Main Authors: Liao, Tingfeng, Xiong, Lijiao, Wang, Xiaohao, Yang, Shu, Liang, Zhen
Format: Article
Language:English
Subjects:
Adipocytes
Atrophy
Autophagy
Body fat
Developmental stages
Diabetes
Diet
Disease
Disease susceptibility
Drug therapy
Exercise
Inflammation
Insulin resistance
Lipids
Metabolic disorders
Mitochondria
Mitochondrial DNA
Musculoskeletal system
Myasthenia gravis
Neuromuscular junctions
Obesity
Oxidation
Oxidative stress
Physical fitness
Proteins
Review
Sarcopenia
Type 2 diabetes
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Obese sarcopenia is a severe and prevalent disease in an aging society. Compared to sarcopenia alone, the development and advanced stage of obesity sarcopenia is faster and more severe. Diagnosis of the cause of adipocyte accumulation is also more complicated; however, no effective pharmacological treatment is available. Chronic inflammation is one of the causes of sarcopenia, and obese patients, who are more likely to develop chronic inflammation, may simultaneously suffer from obesity and sarcopenia. Mitochondrial metabolic disorders have been more easily observed in the tissue cells of patients with obesity and sarcopenia. Mitochondrial metabolic disorders include abnormal mtDNA release, mitochondrial autophagy, and dynamic mitochondrial disorders. Therefore, this review will reveal the mechanism of development of obesity myasthenia gravis from the perspective of mitochondria and discuss the currently existing small-molecule drugs.
ISSN:1758-5996
1758-5996
DOI:10.1186/s13098-023-01192-w